All Sides of the Joint: Integrated TGCT Care Across Specialties
A.J. Gelderblom, MD, PhD
Michiel van de Sande, MD, PhD
Chelsea Cole, MD
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
Komal Jhaveri, MD, FACP
Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
Giuseppe Curigliano, MD, PhD
Safety of CDK4/6 Inhibitors: Anticipation, Prevention, and Management of Adverse Events
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
Spotlight on Latin America: Closing the Gap
Cynthia Villarreal-Garza, MD, DSc
Routes Reconsidered: A Case-Based Debate in SERD Selection
MOA: CDH6-Targeted Antibody-Drug Conjugates
Kathleen Moore, MD, MS
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
Joyce F. Liu, MD, MPH
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-Making
James M. Cleary, MD, PhD
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
Lauren A. Byers, MD
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC
Luis Paz-Ares, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.